While Dyne Therapeutics Inc has overperformed by 6.99%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, DYN fell by -29.84%, with highs and lows ranging from $35.90 to $6.36, whereas the simple moving average jumped by 32.47% in the last 200 days.
On October 10, 2025, Oppenheimer Downgraded Dyne Therapeutics Inc (NASDAQ: DYN) to Perform. A report published by Raymond James on August 25, 2025, Upgraded its rating to ‘Strong Buy’ for DYN. Bernstein also rated DYN shares as ‘Mkt Perform’, setting a target price of $13 on the company’s shares in an initiating report dated June 24, 2025. Raymond James Initiated an Outperform rating on June 11, 2025, and assigned a price target of $37. Oppenheimer initiated its ‘Outperform’ rating for DYN, as published in its report on June 02, 2025. Evercore ISI’s report from May 29, 2025 suggests a price prediction of $46 for DYN shares, giving the stock a ‘Outperform’ rating. BMO Capital Markets also rated the stock as ‘Outperform’.
Analysis of Dyne Therapeutics Inc (DYN)
Dyne Therapeutics Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -61.32% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 16.83, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and DYN has an average volume of 2.64M. On a monthly basis, the volatility of the stock is set at 6.07%, whereas on a weekly basis, it is put at 6.01%, with a gain of 13.53% over the past seven days. Furthermore, long-term investors anticipate a median target price of $34.50, showing growth from the present price of $16.53, which can serve as yet another indication of whether DYN is worth investing in or should be passed over.
How Do You Analyze Dyne Therapeutics Inc Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 22.94%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 71.83% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
